PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Pre-registration PIK3CA Mutant Inclusion * Clinical T2-T4c, any N, M0 invasive ER+ (Allred Score of 6-8) and HER2 negative (0 or 1+ by IHC or FISH negative for amplification) breast cancer, by AJCC 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node. Note: Patients with invasive ER+ (Allred Score of 6-8) HER2- breast cancer or DCIS in the contralateral breast the patient are eligible * Female ≥18 years of age * ECOG performance status of 0, 1 or 2 * Life expectancy \> 4 months * Premenopausal, patient must be willing to comply with pregnancy requirements * Adequate organ and marrow function * leukocytes ≥ 3,000/mcL * absolute neutrophil count ≥ 1,500/mcL * platelets ≥ 100,000/mcL * total bilirubin ≤ ULN * AST(SGOT)/ and ALT(SGPT) \< 2.5 X ULN * Creatinine ≤ ULN * Able to understand and willing to sign an IRB-approved written informed consent document Exclusion * Prior treatment of this cancer including: surgery, radiation, chemotherapy, biotherapy, hormonal therapy, investigational agent prior to study entry * Receiving any investigational agents * Prior therapy with any Cdk4 inhibitor * Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism * Uncontrolled intercurrent illness including, but n…